{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:24Z","timestamp":1786325364316,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472016"],"award-info":[{"award-number":["82472016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["23ZDFA014"],"award-info":[{"award-number":["23ZDFA014"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08125-5","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:57:29Z","timestamp":1786323449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual\u2011targeted radioligand therapy with [177Lu]Lu\u2011DOTATATE plus [177Lu]Lu\u2011DOTA\u2011IBA for bone metastases from neuroendocrine neoplasms: a prospective pilot study"],"prefix":"10.1007","author":[{"given":"Shumao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"8125_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol [Internet]. 2017;3:1335. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol [Internet]"},{"key":"8125_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000457954","volume":"106","author":"M Scharf","year":"2018","unstructured":"Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance. Neuroendocrinol [Internet]. 2018;106:30\u20137. https:\/\/doi.org\/10.1159\/000457954.","journal-title":"Neuroendocrinol [Internet]"},{"key":"8125_CR3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR, Cancer. J Clin [Internet]. 2018;68:471\u2009\u2013\u200987. https:\/\/doi.org\/10.3322\/caac.21493","journal-title":"J Clin [Internet]"},{"key":"8125_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MPA.0000000000000267","volume":"44","author":"J Kavecansky","year":"2015","unstructured":"Kavecansky J, Wei L, Caronia L, Ramirez M-T, Bloomston M, Shah MH. Bone Metastases in Well-to-Moderately Differentiated Neuroendocrine Tumors: A Single Institutional Review From the Ohio State University Medical Center. Pancreas [Internet]. 2015;44:198\u2013203. https:\/\/doi.org\/10.1097\/MPA.0000000000000267.","journal-title":"Pancreas [Internet]"},{"key":"8125_CR5","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Intl J Cancer [Internet]. 2016;139:2679\u201386. https:\/\/doi.org\/10.1002\/ijc.30400.","journal-title":"Intl J Cancer [Internet]"},{"key":"8125_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-14-0119","volume":"4","author":"K Van Loon","year":"2015","unstructured":"Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez M-T, et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connections [Internet]. 2015;4:9\u201317. https:\/\/doi.org\/10.1530\/EC-14-0119.","journal-title":"Endocr Connections [Internet]"},{"key":"8125_CR7","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO [Internet]. 2023;41:5049\u201367. https:\/\/doi.org\/10.1200\/JCO.23.01529.","journal-title":"JCO [Internet]"},{"key":"8125_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau F-A, Arsenault F, Saighi N, Bouchard L-O, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging [Internet]. 2019;46:728\u201342. https:\/\/doi.org\/10.1007\/s00259-018-4209-7.","journal-title":"Eur J Nucl Med Mol Imaging [Internet]"},{"key":"8125_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.adro.2019.03.014","volume":"4","author":"M Guan","year":"2019","unstructured":"Guan M, He I, Luu M, David J, Gong J, Placencio-Hickok VR, et al. Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. Adv Radiation Oncol [Internet]. 2019;4:513\u20139. https:\/\/doi.org\/10.1016\/j.adro.2019.03.014.","journal-title":"Adv Radiation Oncol [Internet]"},{"key":"8125_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40265-018-1033-0","volume":"79","author":"AD Herrera-Mart\u00ednez","year":"2019","unstructured":"Herrera-Mart\u00ednez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, G\u00e1lvez Moreno MA, et al. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs [Internet]. 2019;79:21\u201342. https:\/\/doi.org\/10.1007\/s40265-018-1033-0.","journal-title":"Drugs [Internet]"},{"key":"8125_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12885-024-11926-2","volume":"24","author":"E Taherifard","year":"2024","unstructured":"Taherifard E, Bakhtiar M, Mahnoor M, Ahmed R, Cavalcante L, Zhang J, et al. Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. BMC Cancer [Internet]. 2024;24:192. https:\/\/doi.org\/10.1186\/s12885-024-11926-2.","journal-title":"BMC Cancer [Internet]"},{"key":"8125_CR12","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol [Internet]. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol [Internet]"},{"key":"8125_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00458-x","author":"ME Caplin","year":"2021","unstructured":"Caplin ME, Ratnayake GM. Diagnostic and therapeutic advances in neuroendocrine tumours. Nat Rev Endocrinol [Internet]. 2021;17:81\u20132. https:\/\/doi.org\/10.1038\/s41574-020-00458-x","journal-title":"Nat Rev Endocrinol [Internet]"},{"key":"8125_CR14","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO-25-00791","volume":"43","author":"FI Lin","year":"2025","unstructured":"Lin FI, Del Rivero J, Carrasquillo JA, Jha A, Zou J, Shamis I, et al. Phase II Study of177 Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. J Clin Oncol [Internet]. 2025;43:3102\u201312. https:\/\/doi.org\/10.1200\/JCO-25-00791.","journal-title":"J Clin Oncol [Internet]"},{"key":"8125_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med [Internet]. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med [Internet]"},{"key":"8125_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2214\/AJR.20.23349","volume":"217","author":"S Sheikhbahaei","year":"2021","unstructured":"Sheikhbahaei S, Sadaghiani MS, Rowe SP, Solnes LB. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. Am J Roentgenol [Internet]. 2021;217:495\u2013506. https:\/\/doi.org\/10.2214\/AJR.20.23349.","journal-title":"Am J Roentgenol [Internet]"},{"key":"8125_CR17","doi-asserted-by":"publisher","first-page":"znae178","DOI":"10.1093\/bjs\/znae178","volume":"111","author":"S Partelli","year":"2024","unstructured":"Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U, et al. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. Br J Surg [Internet]. 2024;111:znae178. https:\/\/doi.org\/10.1093\/bjs\/znae178.","journal-title":"Br J Surg [Internet]"},{"key":"8125_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","volume":"30","author":"SC Kurz","year":"2024","unstructured":"Kurz SC, Zan E, Cordova C, Troxel AB, Barbaro M, Silverman JS, et al. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res [Internet]. 2024;30:680\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2533.","journal-title":"Clin Cancer Res [Internet]"},{"key":"8125_CR19","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1007\/s00259-025-07235-w","volume":"52","author":"R Kashyap","year":"2025","unstructured":"Kashyap R, Alipour R, Boehm E, Jewell K, RaviKumar AS, Cardin A, et al. Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience. Eur J Nucl Med Mol Imaging [Internet]. 2025;52:3672\u201381. https:\/\/doi.org\/10.1007\/s00259-025-07235-w.","journal-title":"Eur J Nucl Med Mol Imaging [Internet]"},{"key":"8125_CR20","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2009.12.001","author":"SE Pool","year":"2010","unstructured":"Pool SE, Krenning EP, Koning GA, Van Eijck CHJ, Teunissen JJM, Kam B, et al. Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy. Seminars Nuclear Med [Internet]. 2010;40:209\u201318. https:\/\/doi.org\/10.1053\/j.semnuclmed.2009.12.001","journal-title":"Seminars Nuclear Med [Internet]"},{"key":"8125_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/RLU.0000000000004130","volume":"47","author":"JA Naveed Ahmad","year":"2022","unstructured":"Naveed Ahmad JA, Schroeder BB, Ruhoy SM, Kennecke HF, Lin BS. Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy. Clin Nucl Med [Internet]. 2022;47:409\u201313. https:\/\/doi.org\/10.1097\/RLU.0000000000004130.","journal-title":"Clin Nucl Med [Internet]"},{"key":"8125_CR22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269456","author":"KR Chandekar","year":"2025","unstructured":"Chandekar KR, Satapathy S, Ballal S, Yadav MP, Ravindra SG, Rastogi S, et al. Clinical Outcomes of177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience. J Nucl Med [Internet]. 2025;jnumed.125.269456. https:\/\/doi.org\/10.2967\/jnumed.125.269456","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7150\/thno.87345","volume":"14","author":"S Richter","year":"2024","unstructured":"Richter S, Steenblock C, Fischer A, Lemm S, Ziegler CG, Bechmann N, et al. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments. Theranostics [Internet]. 2024;14:17\u201332. https:\/\/doi.org\/10.7150\/thno.87345.","journal-title":"Theranostics [Internet]"},{"key":"8125_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","volume":"48","author":"L Qiu","year":"2023","unstructured":"Qiu L, Wang Y, Liu H, Wang Q, Chen L, Liu L, et al. Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases: A Phase 0\/I Study. Clin Nucl Med [Internet]. 2023;48:489\u201396. https:\/\/doi.org\/10.1097\/RLU.0000000000004634.","journal-title":"Clin Nucl Med [Internet]"},{"key":"8125_CR25","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","volume":"20","author":"Q Wang","year":"2023","unstructured":"WangQ, Yang J, Wang Y, Liu H, Feng Y, Qiu L, et al. Lutetium177-Labeled DOTA-Ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases. Mol Pharm [Internet]. 2023;20:1788\u201395. . https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00978","journal-title":"Mol Pharm [Internet]"},{"key":"8125_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/RLU.0000000000005573","volume":"50","author":"T Xu","year":"2025","unstructured":"Xu T, Wang Y, Liu G, Li H, Qu G, Zhang X, et al. Efficacy and Safety of 177Lu-DOTA-IBA in Tumor Bone Metastasis Treatment: A Prospective Clinical Trial. Clin Nucl Med [Internet]. 2025;50:119\u201324. https:\/\/doi.org\/10.1097\/RLU.0000000000005573.","journal-title":"Clin Nucl Med [Internet]"},{"key":"8125_CR27","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2967\/jnumed.123.265484","volume":"64","author":"J Hemmingsson","year":"2023","unstructured":"Hemmingsson J, Svensson J, Hallqvist A, Smits K, Johanson V, Bernhardt P. Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177 Lu]Lu-DOTATATE Treatment. J Nucl Med [Internet]. 2023;64:1456\u201362. https:\/\/doi.org\/10.2967\/jnumed.123.265484.","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-14-0119","volume":"4","author":"K Van Loon","year":"2015","unstructured":"Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez M-T, et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connections [Internet]. 2015;4:9\u201317. https:\/\/doi.org\/10.1530\/EC-14-0119.","journal-title":"Endocr Connections [Internet]"},{"key":"8125_CR29","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/JCO.19.00980","volume":"37","author":"A Carmona-Bayonas","year":"2019","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Lamarca \u00c1, Barriuso J, Casta\u00f1o \u00c1, Benavent M, et al. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. JCO [Internet]. 2019;37:2571\u201380. https:\/\/doi.org\/10.1200\/JCO.19.00980.","journal-title":"JCO [Internet]"},{"key":"8125_CR30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet [Internet]. 2016;387:968\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X.","journal-title":"Lancet [Internet]"},{"key":"8125_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI Procedure Standard\/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med [Internet]. 2023;64:204\u201310. https:\/\/doi.org\/10.2967\/jnumed.122.264860.","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR32","doi-asserted-by":"publisher","first-page":"e13479","DOI":"10.1111\/jne.13479","volume":"37","author":"V Prasad","year":"2025","unstructured":"Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose CM, Pavel M, et al. Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force. J Neuroendocrinol [Internet]. 2025;37:e13479. https:\/\/doi.org\/10.1111\/jne.13479.","journal-title":"J Neuroendocrinol [Internet]"},{"key":"8125_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2214\/AJR.21.27159","volume":"218","author":"SJ Galgano","year":"2022","unstructured":"Galgano SJ, Iravani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response\u2014 AJR Expert Panel Narrative Review. Am J Roentgenol [Internet]. 2022;218:767\u201380. https:\/\/doi.org\/10.2214\/AJR.21.27159.","journal-title":"Am J Roentgenol [Internet]"},{"key":"8125_CR34","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1007\/s00259-025-07351-7","volume":"52","author":"S Satapathy","year":"2025","unstructured":"Satapathy S, Aggarwal P, Sood A, Chandekar KR, Das CK, Gupta R, et al. Novel framework for response evaluation criteria in grade 1\/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial. Eur J Nucl Med Mol Imaging [Internet]. 2025;52:4902\u201312. https:\/\/doi.org\/10.1007\/s00259-025-07351-7.","journal-title":"Eur J Nucl Med Mol Imaging [Internet]"},{"key":"8125_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1874471008666150313105000","volume":"9","author":"C Bal","year":"2015","unstructured":"Bal C, Arora G, Kumar P, Damle N, Das T, Chakraborty S, et al. Pharmacokinetic, Dosimetry and Toxicity Study of177 Lu-EDTMP in Patients: Phase 0\/I study. CRP [Internet]. 2015;9:71\u201384. https:\/\/doi.org\/10.2174\/1874471008666150313105000.","journal-title":"CRP [Internet]"},{"key":"8125_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2967\/jnumed.115.155762","volume":"56","author":"P Thapa","year":"2015","unstructured":"Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP, Basu S. Clinical Efficacy and Safety Comparison of177 Lu-EDTMP with153 Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases. J Nucl Med [Internet]. 2015;56:1513\u20139. https:\/\/doi.org\/10.2967\/jnumed.115.155762.","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/cbr.2020.4323","volume":"36","author":"E Askari","year":"2021","unstructured":"Askari E, Harsini S, Vahidfar N, Divband G, Sadeghi R. 177 Lu-EDTMP for Metastatic Bone Pain Palliation: A Systematic Review and Meta-Analysis. Cancer Biotherapy Radiopharmaceuticals [Internet]. 2021;36:383\u201390. https:\/\/doi.org\/10.1089\/cbr.2020.4323.","journal-title":"Cancer Biotherapy Radiopharmaceuticals [Internet]"},{"key":"8125_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1010658522847","volume":"66","author":"R Sciuto","year":"2001","unstructured":"Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, et al. Metastatic bone pain palliation with 89-Sr and 186\u2010Re\u2010HEDP in breast cancer patients. Breast Cancer Res Treat [Internet]. 2001;66:101\u20139. https:\/\/doi.org\/10.1023\/A:1010658522847.","journal-title":"Breast Cancer Res Treat [Internet]"},{"key":"8125_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","volume":"63","author":"CC Parker","year":"2013","unstructured":"Parker CC, Pascoe S, Chodacki A, O\u2019Sullivan JM, Germ\u00e1 JR, O\u2019Bryan-Tear CG, et al. A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. Eur Urol [Internet]. 2013;63:189\u201397. https:\/\/doi.org\/10.1016\/j.eururo.2012.09.008.","journal-title":"Eur Urol [Internet]"},{"key":"8125_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/RLU.0000000000006475","volume":"51","author":"Q Hua","year":"2026","unstructured":"Hua Q, Wang Y, Pei W, Zhao Y, Wang W, Chen Y. Excellent Response to 177Lu-DOTA-IBA Therapy of Patients With Multiple Skeletal Metastases. Clin Nuclear Med [Internet]. 2026;51:565\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000006475.","journal-title":"Clin Nuclear Med [Internet]"},{"key":"8125_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/cancers16010200","volume":"16","author":"H Lee","year":"2023","unstructured":"LeeH, Kipnis ST, Niman R, O\u2019Brien SR, Eads JR, Katona BW, et al. Prediction of 177Lu-DOTATATE therapy outcomes in neuroendocrine tumor patients using semi-automatic tumor delineation on 68Ga-DOTATATE PET\/CT. Cancers [Internet]. 2023;16:200. . https:\/\/doi.org\/10.3390\/cancers16010200","journal-title":"Cancers [Internet]"},{"key":"8125_CR42","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.7150\/thno.19588","volume":"7","author":"E Hindi\u00e9","year":"2017","unstructured":"Hindi\u00e9 E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics [Internet]. 2017;7:1159\u201363. https:\/\/doi.org\/10.7150\/thno.19588.","journal-title":"Theranostics [Internet]"},{"key":"8125_CR43","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, et al. Quantitative68 Ga-DOTATATE PET\/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with177 Lu-DOTATATE. J Nucl Med [Internet]. 2021;62:1406\u201314. https:\/\/doi.org\/10.2967\/jnumed.120.256727.","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR44","doi-asserted-by":"publisher","first-page":"1657202","DOI":"10.3389\/fendo.2025.1657202","volume":"16","author":"L Li","year":"2025","unstructured":"Li L, Gao H, Shao Y, Zhu X. Analysis of the clinical characteristics of bone metastases after pheochromocytoma\/paraganglioma surgery. Front Endocrinol [Internet]. 2025;16:1657202. https:\/\/doi.org\/10.3389\/fendo.2025.1657202.","journal-title":"Front Endocrinol [Internet]"},{"key":"8125_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/RLU.0000000000003412","volume":"46","author":"P Thuillier","year":"2021","unstructured":"Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges J-P, et al. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT\/CT and 68Ga-DOTATOC PET\/CT in Patients With Neuroendocrine Tumors: A Feasibility Study. Clin Nucl Med [Internet]. 2021;46:111\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003412.","journal-title":"Clin Nucl Med [Internet]"},{"key":"8125_CR46","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-025-07221-2","volume":"52","author":"T Ruhwedel","year":"2025","unstructured":"Ruhwedel T, Rogasch J, Schatka I, Galler M, Steinhagen P, Wetz C, et al. Beyond similarities: overall survival and prognostic insights from [177Lu]Lu-DOTATOC therapy in neuroendocrine tumors. Eur J Nucl Med Mol Imaging [Internet]. 2025;52:3662\u201371. https:\/\/doi.org\/10.1007\/s00259-025-07221-2.","journal-title":"Eur J Nucl Med Mol Imaging [Internet]"},{"key":"8125_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","volume":"59","author":"H Bergsma","year":"2018","unstructured":"Bergsma H, Van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, et al. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with177 Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med [Internet]. 2018;59:452\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.189712.","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR48","doi-asserted-by":"publisher","first-page":"e250025","DOI":"10.1530\/ERC-25-0025","volume":"32","author":"Y Kusne","year":"2025","unstructured":"Kusne Y, Patnaik MM, Halfdanarson TR, Sonbol MB. Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk? Endocrine-Related Cancer [Internet]. 2025;32:e250025. https:\/\/doi.org\/10.1530\/ERC-25-0025.","journal-title":"Endocrine-Related Cancer [Internet]"},{"key":"8125_CR49","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2967\/jnumed.121.263056","volume":"63","author":"S Alsadik","year":"2022","unstructured":"Alsadik S, Gnanasegaran G, Chen L, Mandair D, Toumpanakis C, Caplin M, et al. Safety of Peptide Receptor Radionuclide Therapy with177 Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease. J Nucl Med [Internet]. 2022;63:1503\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263056.","journal-title":"J Nucl Med [Internet]"},{"key":"8125_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","volume":"48","author":"AB Peterson","year":"2023","unstructured":"Peterson AB, Wang C, Wong KK, Frey KA, Muzik O, Schipper MJ, et al. 177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers. Clin Nucl Med [Internet]. 2023;48:393\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000004599.","journal-title":"Clin Nucl Med [Internet]"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08125-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:57:30Z","timestamp":1786323450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08125-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":50,"alternative-id":["8125"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08125-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional committee, as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any animal experiments.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agree to the publication of this research.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}